Lilly Cuts 340B Discounts to Noncompliant Hospitals
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly has begun eliminating mandated 340B price breaks to a few dozen hospitals that failed to provide comprehensive claims data, after warning of the move earlier this month as part of a January policy.
- The 340B policy went into effect Feb. 1, and Lilly said more than 2,300 hospitals had complied with its data demand while up to 1,000 had not, with the company pressing roughly 50 larger hospital systems to supply the data.
- Lilly framed the cuts as an effort to reduce what it calls duplicate discounts paid to hospitals participating in the federal drug discount program.
- Hospital trade groups argue the move is unlawful and are asking Congress to intervene, creating a direct clash between manufacturer and provider interests over the program's compliance rules.
- Larger hospital systems around the U.S. refused to provide the data despite follow-up letters, making them the primary targets of the enforcement wave even as thousands of other hospitals complied.
Why it matters: By withholding 340B discounts from noncompliant hospitals, Lilly is unilaterally rewriting the data-sharing terms of a federal drug discount program that safety-net hospitals rely on for lower-cost medicines, putting pressure on the dozens of large holdouts and inviting a legal fight that hospital groups want Congress to settle.
